News Sharing
For sharing news, please enter the email address of you and the receiver, then press SEND button.*Mandatory Fields
Receiver*
Enter email addresses, separated by semicolon (;). E.g. a@a.com;b@b.com
Your email address*
 Content Sharing
<Research>CCBI Elevates INNOVENT BIO (01801.HK) TP to $100, Keeps Rating at Outperform
INNOVENT BIO (01801.HK) expressed confidence at its R&D meeting in achieving its sales target of RMB20 billion by the end of 2027, compared to CCBI's expectation of RMB22.9...
Reset
Send
The window will close in 5 seconds
<Research>CCBI Elevates INNOVENT BIO (01801.HK) TP to $100, Keeps Rating at Outperform
Close
Recommend
7
Positive
11
Negative
4
 
SHORT SELL
 
STOCK INFO

INNOVENT BIO (01801.HK)  +0.350 (+0.407%)    Short selling $114.29M; Ratio 16.500%   expressed confidence at its R&D meeting in achieving its sales target of RMB20 billion by the end of 2027, compared to CCBI's expectation of RMB22.9 billion, according to CCBI's research report.

Furthermore, the company was also confident that, by the end of 2023, at least five key drug molecules will enter Phase 3 multi-regional clinical trials, and believed that the combination therapy of new-generation bispecific antibody and antibody drug conjugate (ADC) will become a new trend and direction for immuno-oncology therapy.

Related NewsBOCOMI Ratings, TPs on CN Pharma Stocks (Table)
CCBI believed that short-term catalysts include potential out-licensing outside the Greater China region and positive clinical results from the company's key clinical-stage drugs. The broker listed the company as its sector top pick, and elevated its target price from $90 to $100, with rating kept at Outperform.
(HK stocks quote is delayed for at least 15 mins.Short Selling Data as at 2025-07-16 12:25.)

AASTOCKS Financial News
Website: www.aastocks.com
Copyright(C) AASTOCKS.com Limited 2000. All rights reserved.
Disclaimer: AASTOCKS.com Ltd, HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the Information provided but do not guarantee its accuracy or reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.